Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis:Iimplications for pancreatic carcinogenesis

Laboratory Investigation

Volumn 89, Issue 5, 2009, Pages 489-497

  Bhanot, Umesh K ^a   Möller, Peter ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Pancreas; Pancreatic carcinogenesis; Pancreatitis; Parenchymal injury

Indexed keywords

ALCOHOL; ANGIOTENSIN II; CASPASE 3; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; SERINE PROTEASE INHIBITOR KAZAL TYPE 1; SERINE PROTEINASE INHIBITOR; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSINOGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; DEATH RECEPTOR; PTGS2 PROTEIN, HUMAN;

APOPTOSIS; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL DAMAGE; CHRONIC PANCREATITIS; CYSTIC FIBROSIS; DIABETES MELLITUS; EXOCRINE CELL; HUMAN; IMMUNE RESPONSE; NONHUMAN; PANCREAS CANCER; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; REVIEW; SENTINEL EVENT; STELLATE CELL; IMMUNOLOGY; METABOLISM; PANCREAS DUCT; PANCREAS TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CYCLOOXYGENASE 2; HEDGEHOG PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; RECEPTORS, DEATH DOMAIN; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 65649115826     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.19     Document Type: Review

References (73)

1. Mitchell RM, Byrne MF, Baillie J. Pancreatitis. Lancet 2003;361: 1447-1455.
2. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001;120:682-707.
3. Whitcomb DC. Mechanisms of disease: advances in understanding the mechanisms leading to chronic pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2004;1:46-52.
4. Muddana V, Lamb J, Greer JB, et al. Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population: role of serine protease inhibitor Kazal 1type and alcohol. World J Gastroenterol 2008;14:4486-4491.
5. Stevens T, Conwell DL, Zuccaro G. Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol 2004;99:2256-2270.
6. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997;113:1063-1068.
7. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141-145.
8. Kloppel G, Maillet B. Pseudocysts in chronic pancreatitis: a morphological analysis of 57 resection specimens and 9 autopsy pancreata. Pancreas 1991;6:266-274.
9. Fukumura Y, Suda K, Mitani K, et al. Expression of transforming growth factor beta by small duct epithelium in chronic, cancer-associated, obstructive pancreatitis: an in situ hybridization study and review of the literature. Pancreas 2007;35:353-357.
10. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000;25:213-216.
11. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998;339: 645-652.
12. Apte MV, Haber PS, Applegate TL, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998;43:128-133.
13. Apte MV, Wilson JS. Stellate cell activation in alcoholic pancreatitis. Pancreas 2003;27:316-320.
14. Jaster R, Sparmann G, Emmrich J, et al. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut 2002;51:579-584.
15. Bachem MG, Schneider E, Gross H, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998;115:421-432.
16. Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 2007;117:50-59.
17. Sparmann G, Hohenadl C, Tornoe J, et al. Generation and characterization of immortalized rat pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2004;287:G211-G219.
18. Apte MV, Wilson JS. Mechanisms of pancreatic fibrosis. Dig Dis 2004;22:273-279.
19. Jaster R. Molecular regulation of pancreatic stellate cell function. Mol Cancer 2004;3:26.
20. Hasel C, Rau B, Perner S, et al. Differential and mutually exclusive expression of CD95 and CD95 ligand in epithelia of normal pancreas and chronic pancreatitis. Lab Invest 2001;81:317-326.
21. Bateman AC, Turner SM, Thomas KS, et al. Apoptosis and proliferation f acinar and islet cells in chronic pancreatitis: evidence for differential cell loss mediating preservation of islet function. Gut 2002;50: 542-548.
22. Hasel C, Dü rr S, Rau B, et al. In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas. Lab Invest 2003;83:825-836.
23. Singh L, Bakshi DK, Majumdar S, et al. Mitochondrial dysfunction and apoptosis of acinar cells in chronic pancreatitis. J Gastroenterol 2008;43:473-483.
24. Schrader H, Menge BA, Schneider S, et al. Reduced pancreatic volume and beta-cell area in patients with chronic pancreatitis. Gastroenterology 2008;136:513-522.
25. Hunger RE, Mueller C, Z'graggen K, et al. Cytotoxic cells are activated in cellular infiltrates of alcoholic chronic pancreatitis. Gastroenterology 1997;112:1656-1663.
26. Yamada T, Hashimoto T, Sogawa M, et al. Role of T cells in development of chronic pancreatitis in male Wistar Bonn/Kobori rats: effects of tacrolimus. Am J Physiol Gastrointest Liver Physiol 2001;281:G1397-G1404.
27. Vallance BA, Hewlett BR, Snider DP, et al. T cell-mediated exocrine pancreatic damage in major histocompatibility complex class IIdeficient mice. Gastroenterology 1998;115:978-987.
28. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-747.
29. Diamond AS, Gill RG. An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts. J Immunol 2000;165:247-255.
30. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferongamma. Annu Rev Immunol 1997;15:749-795.
31. Wenig BM. Inflammatory, infectious, and other non-neo-plastic disorders of the pancreas. In: Odze RD, Goldblum JR, Crawford JM (eds). Surgical Pathology of the GI tract, Liver, Biliary tract and Pancreas, 1st edn. Saunders WB: Philadelphia, 2004, pp 673-697.
32. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NFkB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-820.
33. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, et al. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 2003;52:2274-2278.
34. Mi QS, Ly D, Lamhamedi-Cherradi SE, et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 2003;52:1967-1975.
35. Klein D, Barbé-Tuana F, Pugliese A, et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 2005;48: 268-276.
36. Ben Neriah Y, Schmitz ML. Of mice and men. EMBO Rep 2004;5: 668-673.
37. Hasel C, Bhanot UK, Heydrich R, et al. Parenchymal regression in chronic pancreatitis spares islets reprogrammed for the expression of NFkappaB and IAPs. Lab Invest 2005;85:1263-1275.
38. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999;18:6910-6924.
39. Schmid RM, Adler G. NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases. Gastroenterology 2000;118: 1208-1228.
40. Steinle AU, Weidenbach H, Wagner M, et al. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology 1999;116:420-430.
41. Chen X, Ji B, Han B, et al. NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response. Gastroenterology 2002;122:448-457.
42. Eldor R, Yeffet A, Baum K, et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci USA 2006;103:5072-5077.
43. Heimberg H, Heremans Y, Jobin C, et al. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. Diabetes 2001;50:2219-2224.
44. Rehman KK, Bertera S, Bottino R, et al. Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. J Biol Chem 2003;278: 9862-9868.
45. Robbins MA, Maksumova L, Pocock E, et al. Nuclear factor-kappaB translocation mediates double-stranded ribonucleic acid-induced NIT-1 beta-cell apoptosis and up-regulates caspase-12 and tumor necrosis factor receptor-associated ligand (TRAIL). Endocrinology 2003;144:4616-4625.
46. Weber CK, Adler G. From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology 2001;1: 356-362.
47. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003;63:1059-1066.
48. Wang Y, Cui H, Schroering A, et al. NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol 2002;4:888-893.
49. Häcker H, Karin M. Is NF-kappaB2/p100 a direct activator of programmed cell death? Cancer Cell 2002;2:431-433.
50. Deveraux QL, Reed JC. IAP family proteins suppressors of apoptosis. Genes Dev 1999;13:239-252.
51. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320.
52. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 1998;64: 7183-7190.
53. Dohi T, Salz W, Costa M, et al. Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Rep 2006;7:438-443.
54. Ou D, Metzger DL, Wang X, et al. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia 2002;45:1678-1688.
55. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
56. Bhanot UK, Möller P, Hasel C. Dichotomy of fates of pancreatic epithelia in chronic pancreatitis: apoptosis versus survival. Trends Mol Med 2006;12:351-357.
57. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-169.
58. Whitcomb DC. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004;287:G315-G319.
59. Leach SD. Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and Notch. J Clin Gastroenterol 2005;39:S78-S82.
60. Colby JK, Klein RD, McArthur MJ, et al. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008;10:782-796.
61. Yamamoto M, Otani M, Otsuki M. A new model of chronic pancreatitis in rats. Am J Physiol Gastrointest Liver Physiol 2006;291: G700-G708.
62. Rooman I, De Medts N, Baeyens L, et al. Expression of the Notch signaling pathway and effect on exocrine cell proliferation in adult rat pancreas. Am J Pathol 2006;169:1206-1214.
63. Artavanis-Tsakonas S, Rand MD, et al. Notch signaling: cell fate control and signal integration in development. Science 1999;284: 770-776.
64. Gray GE, Mann RS, Mitsiadis E, et al. Human ligands of the Notch receptor. Am J Pathol 1999;154:785-794.
65. Jensen JN, Cameron E, Garay MV, et al. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology 2005;128:728-741.
66. Bhanot U, Köhntop R, Hasel C, et al. Evidence of Notch pathway activation in the ectatic ducts of chronic pancreatitis. J Pathol 2008;214:312-319.
67. De La O JP, Emerson LL, Goodman JL, et al. Notch and Kras reprogram pancreatic acinar cell to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 2008;105:18907-18912.
68. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alphainduced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-576.
69. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54.
70. Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle 2007;6:1553-1557.
71. Morton JP, Mongeau ME, Klimstra DS, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 2007;104:5103-5108.
72. Fendrich V, Esni F, Garay MV, et al. Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology 2008;135:621-631.
73. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.